The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias

Jasiński, Marcin; Biliński, Jarosław; Basak, Grzegorz W.

doi:10.3389/fonc.2021.741376

Cited by 6 publications

(5 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, these microorganisms produce metabolites such as short-chain fatty acids (SCFAs), which could have anti-carcinogenic properties. The most predominant SCFAs, acetate, propionate, and butyrate, play crucial roles in ion absorption and intestinal motility (Jasiński et al, 2021). In particular, butyrate has been studied for its anti-inflammatory properties (Ubeda et al, 2010;Canani et al, 2011;Zimmerman et al, 2012;Bin et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Role of the gut microbiota in hematologic cancer

Guevara-Ramírez,

Cadena-Ullauri,

Paz-Cruz

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

Hematologic neoplasms represent 6.5% of all cancers worldwide. They are characterized by the uncontrolled growth of hematopoietic and lymphoid cells and a decreased immune system efficacy. Pathological conditions in hematologic cancer could disrupt the balance of the gut microbiota, potentially promoting the proliferation of opportunistic pathogens. In this review, we highlight studies that analyzed and described the role of gut microbiota in different types of hematologic diseases. For instance, myeloma is often associated with Pseudomonas aeruginosa and Clostridium leptum, while in leukemias, Streptococcus is the most common genus, and Lachnospiraceae and Ruminococcaceae are less prevalent. Lymphoma exhibits a moderate reduction in microbiota diversity. Moreover, certain factors such as delivery mode, diet, and other environmental factors can alter the diversity of the microbiota, leading to dysbiosis. This dysbiosis may inhibit the immune response and increase susceptibility to cancer. A comprehensive analysis of microbiota-cancer interactions may be useful for disease management and provide valuable information on host-microbiota dynamics, as well as the possible use of microbiota as a distinguishable marker for cancer progression.

show abstract

Section: Introductionmentioning

confidence: 99%

Role of the gut microbiota in hematologic cancer

Guevara-Ramírez,

Cadena-Ullauri,

Paz-Cruz

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Minimal residual disease (MRD) negativity in multiple myeloma is associated with higher E hallii abundance in their intestinal microbiota composition [14]. Thus, it is possible that the composition of gut microbiota in MM patients has great influence on the effect of immunotherapy, especially taking into account that MM is closely related to immune response [46]. Mechanistically, Microbial metabolites SCFAs can suppress proinflammatory cytokines IL-6 and TNF-α; whereas they may increase IL-10, Th17 and Th1 cells [47].…”

Section: Discussionmentioning

confidence: 99%

Gut microbiota deficiency ameliorates multiple myeloma and myeloma-related bone disease by Th17 cells in mice models

Liu,

Xie,

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Purpose: Multiple myeloma, the second most common hematological tumor, is currently incurable. Multiple myeloma-related bone disease is a characteristic clinical symptom that seriously affects the survival and prognosis of patients. In recent years, gut microbiota has been shown to play an important role in the occurrence and development of multiple myeloma. However, whether and how it affects the development of myelomatous bone disease is unclear. Methods: To investigate the mechanism and influence of the microbiota on multiple myeloma and myeloma bone disease, a myeloma-gut microbiota deletion mice model was established. 16S rRNA sequencing was used to analysis of bacterial flora changes. Histochemical staining and bone micro-CT were used to assess the severity of bone disease. Bone marrow tumor load and spleen Th17 cells were detected by flow cytometry. Results: Histochemical staining revealed a reduced tumor burden after eliminating gut microbial communities in mice by administering a mixture of antibiotics. According to the 16S rRNA sequencing of intestinal contents, antibiotic treatment resulted in a significant change in the microbiota of the mice. Bone micro-CT demonstrated that antibiotic treatment could reduce bone lesions caused by myeloma while increasing mineral density, bone volume fraction, trabecular bone thickness, and trabecular number. Meanwhile, histochemical staining of the bone found that the enhanced bone resorption was weakened by the change of flora. These results were consistent with the concentration of IL17 in serum and the frequency of Th17 cells in spleen. Conclusions: Herein, the effects of the gut microbiome on myeloma bone disease are investigated for the first time, providing new insight into its pathogenesis and suggesting that gut microbiota may serve as a therapeutic target in multiple myeloma-associated bone diseases.

show abstract

“…The immune regulatory effect of the intestinal microbiota extends beyond the gut, primarily through small molecules they produce ( 8 ). The anaerobic environment in the gastrointestinal tract enables bacteria to ferment and produce metabolites with immune activity that can enter the systemic circulation, especially butyrate produced by Clostridium butyricum ( 9 ). Disturbance of the intestinal microbiota and an abnormal increase in its metabolites can lead to continuous stimulation signals throughout the entire gastrointestinal tract and trigger various diseases, including tumors ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

Changes in the intestinal microbiota of multiple myeloma patients living in high‑altitude and cold regions analyzed using 16s rRNA high‑throughput sequencing

Liang,

Guo,

Jin

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Multiple myeloma (MM) is a plasma cell clonal disease and these plasma cells can survive in the gut. The intestinal microbiota is a complex ecosystem and its dysfunction can release persistent stimulus signals that trigger genetic mutations and clonal evolution in the gut. The present study analyzed the intestinal microbiota in fecal samples of MM patients in high-altitude and cold regions of China using 16s rRNA sequencing and analyzed significantly enriched species at the phylum and genus levels. Although no significant difference in the alpha diversity was observed between the MM and control groups, a significant difference was noted in the beta diversity. A total of 15 significant differential bacteria at the genus level were found between the two groups, among which Bacteroides , Streptococcus , Lactobacillus and Alistipes were significantly enriched in the MM group. The present study also constructed a disease diagnosis model using Random Forest analysis and verified its accuracy using receiver operating characteristic analysis. In addition, using correlation analysis, it demonstrated that the composition of the intestinal microbiota in patients with MM was associated with complement levels. Notably, the present study predicted that the signaling and metabolic pathways of the intestinal microbiota affected MM progression through Kyoto Encyclopedia of Genes and Genomes functional analysis. The present study provides a new approach for the prevention and treatment of MM, in which the intestinal microbiota may become a novel therapeutic target for MM.

show abstract

The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias

Cited by 6 publications

References 91 publications

Role of the gut microbiota in hematologic cancer

Role of the gut microbiota in hematologic cancer

Gut microbiota deficiency ameliorates multiple myeloma and myeloma-related bone disease by Th17 cells in mice models

Changes in the intestinal microbiota of multiple myeloma patients living in high‑altitude and cold regions analyzed using 16s rRNA high‑throughput sequencing

Contact Info

Product

Resources

About